1. Home
  2. RCS vs SENS Comparison

RCS vs SENS Comparison

Compare RCS & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Strategic Income Fund Inc.

RCS

PIMCO Strategic Income Fund Inc.

HOLD

Current Price

$5.24

Market Cap

251.8M

Sector

Finance

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$5.51

Market Cap

301.2M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCS
SENS
Founded
1994
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Industrial Machinery/Components
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
251.8M
301.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RCS
SENS
Price
$5.24
$5.51
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$18.38
AVG Volume (30 Days)
151.0K
551.8K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
10.12%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,389,000.00
Revenue This Year
N/A
$74.15
Revenue Next Year
N/A
$58.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
19.85
52 Week Low
$5.09
$0.41
52 Week High
$8.00
$8.75

Technical Indicators

Market Signals
Indicator
RCS
SENS
Relative Strength Index (RSI) 37.72 37.97
Support Level $5.09 $5.40
Resistance Level $5.68 $5.94
Average True Range (ATR) 0.09 0.46
MACD -0.03 -0.21
Stochastic Oscillator 11.76 15.22

Price Performance

Historical Comparison
RCS
SENS

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: